Fulvia C. Daffara
Turin, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.
Journal: The Journal of pharmacy and pharmacology
Published: June 06, 2017
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
Journal: The Journal of clinical endocrinology and metabolism
Published: August 02, 2016
Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?
Journal: Journal of endocrinological investigation
Published: September 08, 2015
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.
Journal: The Journal of clinical endocrinology and metabolism
Published: January 07, 2015
Surgical remission of Cushing's syndrome reduces cardiovascular risk.
Journal: European journal of endocrinology
Published: May 08, 2014
MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations.
Journal: Human pathology
Published: December 30, 2013
Management of adrenal cancer: a 2013 update.
Journal: Journal of endocrinological investigation
Published: December 12, 2013
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Journal: European journal of endocrinology
Published: May 25, 2013
Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 02, 2012
Management of adjuvant mitotane therapy following resection of adrenal cancer.
Journal: Endocrine
Published: April 01, 2012
Mitotane treatment for adrenocortical carcinoma: an overview.
Journal: Minerva endocrinologica
Published: March 03, 2012
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Journal: European journal of endocrinology
Published: December 23, 2011
Last Updated: 09/26/2026